Cachexia in pancreatic cancer: New treatment options and measures of success

HPB

Volumn 12, Issue 5, 2010, Pages 323-324

  Fearon, Kenneth C H ^a   Baracos, Vickie E ^b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; MYOSTATIN; POTASSIUM;

BODY COMPOSITION; CACHEXIA; CANCER STAGING; CANCER THERAPY; COMPUTER ASSISTED TOMOGRAPHY; EDITORIAL; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CANCER; POTASSIUM BLOOD LEVEL; QUALITY OF LIFE; WASTING SYNDROME;

EID: 77953574566     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/j.1477-2574.2010.00178.x     Document Type: Editorial

References (13)

1. Wigmore SJ, Plester CE, Richardson RA, Ross JA, Fearon KCH. (1997) Changes in nutritional status associated with unresectable pancreatic cancer. Br J Cancer 75:106-109.
2. Aslani A, Gill AJ, Roach PJ, Allen BJ, Smith RC. (2010) Preoperative body composition is influenced by the stage of operable pancreatic adenocarcinoma but does not predict survival after Whipple's resection. HPB 12:325-332.
3. Tan BH, Birdsell LA, Martin L, Baracos VE, Fearon KC. (2009) Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res 15:6973-6979.
4. Bachmann J, Ketterer K, Marsch C, Fechtner K, Krakowski-Roosen H, B̈chler MW et al. (2009) Pancreatic cancer-related cachexia: influence on metabolism and correlation to weight loss and pulmonary function. BMC Cancer 9:255.
5. Prado CM, Birdsell LA, Baracos VE. (2009) The emerging role of computerized tomography in assessing cancer cachexia. Curr Opin Support Palliat Care 3:269-275.
6. Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. (2008) A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 33:997-1006.
7. Lowe SS, Watanabe SM, Baracos VE, Courneya KS. (2009) Associations between physical activity and quality of life in cancer patients receiving palliative care: a pilot survey. J Pain Symptom Manage 38:785-796.
8. Dahele M, Fearon K. (2004) Research methodology: cancer cachexia syndrome. Palliat Med 18:409-417.
9. Moses AWG, Slater C, Preston T, Barber MD, Fearon KCH. (2004) Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Cancer 90:996-1002.
10. Prado CM, Baracos VE, McCargar LJ, Mourtzakis M, Mulder KE, Reiman T et al. (2007) Body composition as an independent determinant of fluorouracil-based chemotherapy toxicity. Clin Cancer Res 13:3264-3268.
11. Prado CM, Baracos VE, McCargar L, Reiman T, Mourtzakis M, Tonkin K et al. (2009) Sarcopenia as a determinant of chemotherapy toxicity and time to tumour progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 15:2920-2926.
12. Ross PJ, Ashley S, Norton A, Priest K, Waters JS, Eisen T et al. (2004) Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancer? Br J Cancer 90:1905-1911.
13. Fearon KCH. (2008) Cancer cachexia: developing multimodal therapy for a multidimensional problem. Eur J Cancer 44:1124-1132.